Allergan’s Botox For Removing Glabellar Lines Yet To Receive SFDA Approval
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline China Investment introduced Allergan-developed Botox into China in October 2006 as a drug for one-sided facial muscle spasms and eyelid twitching. However, the popular wrinkle-removing Botox injection has yet to receive China's State FDA approval for treatment of glabellar lines between eyebrows. GSK officials say Botox for removing glabellar lines is still in clinical trials, but declined to comment on the progress or expected market prospects for the drug in China. On the other hand, botulinum toxin type A produced by local firm Lanzhou Institute of Biological Products has captured the China market. Although it has not been approved for glabellar lines removal, the drug has gained widespread cosmetic use in many domestic plastics institutions. (Click here for more - Chinese Language)